6533b859fe1ef96bd12b6fb9
RESEARCH PRODUCT
Is Danggui Safe to be Taken by Breast Cancer Patients?-A Skepticism Finally Answered by Comprehensive Preclinical Evidence.
Grace Gar-lee YueGrace Gar-lee YueLok-sze WongLok-sze WongHoi-wing LeungHoi-wing LeungSi GaoSi GaoJulia Yuen-shan TsangZhi-xiu LinBonita Ka-bo LawGary Man-kit TseClara Bik-san LauClara Bik-san Lausubject
0301 basic medicineOncologysafetymedicine.medical_specialtyprimary breast cancer cellsmedicine.drug_classXenotransplantationmedicine.medical_treatmentTraditional Chinese medicine03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinemedicinePharmacology (medical)skin and connective tissue diseasesOriginal ResearchPharmacologySafety studiesbusiness.industrylcsh:RM1-950Angelica sinensisChinese herbal medicinesmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyEstrogen030220 oncology & carcinogenesisCancer cellestrogenic herbsBreast cancer cellsPrimary breast cancerbusinessdescription
Angelica sinensis (AS, Danggui) has long been regarded to stimulate breast cancer growth; hence, the use of AS in breast cancer patients remains a major concern for both patients and practitioners. Since safety studies of herbs would be unethical to carry out in patients, the present study aimed to investigate the potential unsafe effects of AS in a systematic pre-clinical approach. Human breast cancer cells, breast orthotopic tumor-bearing mouse models, as well as primary breast cancer cells from patients’ tumors were used to evaluate the effect of AS hot water extract on the progression of breast tumors and/or growth of breast cancer cells. We showed that AS is not that stimulatory in breast cancer both in vitro and in vivo, though AS should still be used with caution in estrogen receptor-positive breast cancer patients. This novel approach of applying breast cancer cell lines, xenograft, and syngeneic tumors models, as well as primary breast cancer cells from patients’ tumors in Chinese medicines safety evaluation was proven feasible. Our finding is important information for patients, Chinese medicine practitioners, and clinicians on the safety use of AS in breast cancer, which will affect future clinical practice.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-06-01 | Frontiers in pharmacology |